{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T16:23:08Z","timestamp":1772209388508,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[1997,1,1]],"date-time":"1997-01-01T00:00:00Z","timestamp":852076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T00:00:00Z","timestamp":1577145600000},"content-version":"vor","delay-in-days":8392,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[1997,1]]},"DOI":"10.1023\/a:1008205424763","type":"journal-article","created":{"date-parts":[[2002,12,22]],"date-time":"2002-12-22T13:47:34Z","timestamp":1040564854000},"page":"79-83","source":"Crossref","is-referenced-by-count":36,"title":["Interleukin-4 in the treatment of AIDS-related Kaposi\u2019s sarcoma"],"prefix":"10.1016","volume":"8","author":[{"given":"A.","family":"Tulpule","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"DeGuzman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.M.","family":"Espina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Mocharnuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Templeton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.M.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.S.","family":"Gill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1023\/A:1008205424763_bb0060","unstructured":"Centers for Disease Control and Prevention: HIV\/AIDS Surveillance Report. February 1993; 1\u201323"},{"key":"10.1023\/A:1008205424763_bb0065","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/S0140-6736(88)90811-2","article-title":"Anti-retroviral effects of interferon-\u03b1 in AIDS-associated Kaposi\u2019s sarcoma","volume":"2","author":"Lane","year":"1988","journal-title":"Lancet"},{"key":"10.1023\/A:1008205424763_bb0070","doi-asserted-by":"crossref","first-page":"335","DOI":"10.7326\/0003-4819-110-5-335","article-title":"Interferon therapy in Kaposi\u2019s sarcoma associated with the acquired immunodeficiency syndrome (AIDS)","volume":"100","author":"Groopman","year":"1989","journal-title":"Ann Intern Med"},{"key":"10.1023\/A:1008205424763_bb0075","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1200\/JCO.1984.2.10.1115","article-title":"Treatment of epidemic Kaposi\u2019s sarcoma with etoposide or a combination of doxorubicin, bleomycin, and vinblastine","volume":"2","author":"Laubenstein","year":"1984","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008205424763_bb0080","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/0002-9343(91)90601-S","article-title":"Systemic treatment of AIDS-related Kaposi\u2019s sarcoma: Results of a randomized trial","volume":"90","author":"Gill","year":"1991","journal-title":"Am J Med"},{"key":"10.1023\/A:1008205424763_bb0085","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1146\/annurev.iy.03.040185.001025","article-title":"Factors affecting B-cell growth and differentiation","volume":"3","author":"Kishimoto","year":"1985","journal-title":"Annu Rev Immunol"},{"key":"10.1023\/A:1008205424763_bb0090","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1084\/jem.165.1.157","article-title":"B-cell stimulatory factor 1 (interleukin-4) is a potent costimulant for normal resting T-lymphocytes","volume":"165","author":"Hu-Li","year":"1987","journal-title":"J Exp Med"},{"key":"10.1023\/A:1008205424763_bb0095","doi-asserted-by":"crossref","first-page":"5654","DOI":"10.1073\/pnas.83.15.5654","article-title":"T-cell and mast cell lines respond to B-cell stimulatory factor-1","volume":"83","author":"Mosmann","year":"1986","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1023\/A:1008205424763_bb0100","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1084\/jem.164.2.580","article-title":"B-cell stimulatory factor 1 (BSF-1) promotes growth of helper T-cell lines","volume":"164","author":"Fernandez-Botran","year":"1986","journal-title":"J Exp Med"},{"key":"10.1023\/A:1008205424763_bb0105","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/0092-8674(89)90925-2","article-title":"Murine interleukin-4 displays potent anti-tumor activity in vivo","volume":"57","author":"Tepper","year":"1989","journal-title":"Cell"},{"key":"10.1023\/A:1008205424763_bb0110","first-page":"a1121","article-title":"Interleukin-4 receptor (IL-4R) expression on AIDS-related Kaposi\u2019s sarcoma (AIDS-KS) cells and inhibition of tumor cell growth and cytokine production by IL-4","volume":"34","author":"Gill","year":"1993","journal-title":"Proc AACR"},{"key":"10.1023\/A:1008205424763_bb0115","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/bjc.1992.243","article-title":"Recombinant human interleukin-4 (IL-4) given as daily subcutaneous injections \u2013 a phase I dose toxicity trial","volume":"66","author":"Gilleece","year":"1992","journal-title":"Br J Cancer"},{"key":"10.1023\/A:1008205424763_bb0120","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/0959-8049(93)90108-R","article-title":"Administered by the intravenous and subcutaneous routes in patients with advanced cancer \u2013 a phase I toxicity study and pharmacokinetic analysis","volume":"29A","author":"Prendrville","year":"1993","journal-title":"Eur J Cancer"},{"key":"10.1023\/A:1008205424763_bb0125","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1200\/JCO.1992.10.11.1802","article-title":"Phase I evaluation of thrice-daily intravenous bolus interleukin-4 in patients with refractory malignancy","volume":"10","author":"Atkins","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008205424763_bb0130","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/oxfordjournals.annonc.a058878","article-title":"A phase I trial of continuous infusion interleukin-4 (IL-4) alone and following interleukin-2 (IL-2) in cancer patients","volume":"5","author":"Sosman","year":"1994","journal-title":"Ann Oncol"},{"key":"10.1023\/A:1008205424763_bb0135","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/00002371-199402000-00009","article-title":"Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma","volume":"15","author":"Margolin","year":"1994","journal-title":"J Immunother with emphasis on Immunol"},{"key":"10.1023\/A:1008205424763_bb0140","doi-asserted-by":"crossref","first-page":"474","DOI":"10.3109\/07357909309018879","article-title":"Interleukin-4 and cancer therapy","volume":"11","author":"Puri","year":"1993","journal-title":"Cancer Invest"},{"issue":"152a","key":"10.1023\/A:1008205424763_bb0145","article-title":"Rapid response of B-cell malignancies induced by interleukin-4","volume":"76","author":"Maher","year":"1990","journal-title":"Blood"},{"key":"10.1023\/A:1008205424763_bb0150","first-page":"70","article-title":"Quantitative competitive polymerase chain reaction for accurate quantitation of HIV DNA and RNA species","volume":"14","author":"Piatek","year":"1993","journal-title":"Biotechniques"},{"key":"10.1023\/A:1008205424763_bb0155","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1099\/0022-1317-73-4-941","article-title":"Recombinant interleukin-4 stimulates human immunodeficiency virus production by infected monocytes and macrophages","volume":"73","author":"Kazazi","year":"1992","journal-title":"J Gen Virol"},{"key":"10.1023\/A:1008205424763_bb0160","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1073\/pnas.87.2.782","article-title":"Tumor necrosis factor \u03b1 functions in an autocrine manner in the induction of human immunodeficiency virus expression","volume":"87","author":"Poli","year":"1990","journal-title":"Proc Nad Acad Sci USA"},{"key":"10.1023\/A:1008205424763_bb0165","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1084\/jem.172.1.151","article-title":"Interleukin-6 induces human immunodeficiency virus espression in infected monocytic cells alone and in synergy with tumor necrosis factor \u03b1 by transcriptional and post transciprtional mchanisms","volume":"172","author":"Poli","year":"1990","journal-title":"J Exp Med"},{"key":"10.1023\/A:1008205424763_bb0170","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1073\/pnas.86.10.3803","article-title":"Potential antiinflammatory effects of interleukin-4: Suppression of human monocyte, tumor necrosis factor \u03b1, interleukin-1 and prostaglandin E2","volume":"86","author":"Hart","year":"1989","journal-title":"Proc Natl Acad Sci (USA)"},{"key":"10.1023\/A:1008205424763_bb0175","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/jlb.47.5.475","article-title":"Interleukin-4 down-regulates interleukin-6 production in human peripheral blood non-uclear cells","volume":"47","author":"Lee","year":"1990","journal-title":"J Leukoc Biol"},{"key":"10.1023\/A:1008205424763_bb0180","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1172\/JCI116294","article-title":"Changes in interleukin-2 and interleukin-4 production in asymptomatic human immunodeficiency virus seropositive individuals","volume":"91","author":"Clerici","year":"1993","journal-title":"J Clin Invest"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419480927?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419480927?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/8\/1\/79\/19480233\/8-1-79.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T17:01:51Z","timestamp":1582218111000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419480927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1997,1]]}},"alternative-id":["S0923753419480927"],"URL":"https:\/\/doi.org\/10.1023\/a:1008205424763","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[1997,1]]}}}